Ixazomib promotes apoptosis in ESCC cells
ESCC cells treated with ixazomib shrank and turned round was observed
microscopically after 48 h, suggestive that ixazomib treatment could
trigger apoptosis. Therefore, we used the Annexin V-FITC/PI assay to
confirm this speculation. In the apoptotic assays, Kyse150 and Kyse510
cells treated with ixazomib at 0.25-1 µM increased the Annexin
V-positive cell populations in a dose-dependent manner (Figure 3A, B).
In accordance with the fluorescence activated cell sorting analyze
results, ixazomib treatment also the activation of caspase 3 and
inhibition of Bcl-2 was strongly induced in ESCC cells (Figure 3C).
These results suggested that ixazomib could trigger apoptosis in ESCC
cells.